Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study
Authors:
- Lucia TaramassoLTLucia Taramasso
- Antonio FallettaAFAntonio Falletta
- Elena RicciERElena Ricci
- Giancarlo OrofinoGOGiancarlo Orofino
- Nicola SquillaceNSNicola Squillace
- Barbara MenzaghiBMBarbara Menzaghi
- Giuseppe Vittorio De SocioGiuseppe Vittorio De Socio
- Chiara MolteniCMChiara Molteni
- Giovanni Francesco PellicanòGiovanni Francesco Pellicanò
- Roberto GulminettiRGRoberto Gulminetti
- Giordano MadedduGiordano Madeddu
- Eleonora SarchiESEleonora Sarchi
Open Access
Abstract
The aim of the present study was to evaluate CD4/CD8 dynamics in patients on dolutegravir (DTG)-based two-drug regimens (2DRs) and compare them with DTG-containing triple-drug regimens (3DRs). A prospective observational study was performed in the context of the SCOLTA cohort. Experienced PWH with HIV-RNA < 50 copies/mL were included if they were on the DTG-2DR, the DTG + tenofovir/emtricitabine (TDF/FTC) regimen, the DTG + tenofovir alafenamide (TAF)/FTC regimen, or the DTG + abacavir/lamivudine (ABC/3TC) regimen; they were followed-up for at least one year. A total of 533 PWH were enrolled, 120 in the DTG + 3TC group, 38 in the DTG + protease inhibitors (PI) group, 67 in the DTG + rilpivirine (RPV) group, 49 in the DTG + TDF/FTC group, 27 in the DTG + TAF/FTC group, and 232 in the DTG + ABC/3TC group. After one year, the CD4/CD8 ratio significantly increased in the PWH treated with DTG + 3TC (+0.08 ± 0.26), DTG + TDF/FTC (+0.1 ± 0.19), and DTG + ABC/3TC (+0.08 ± 0.25). At two years, the CD4/CD8 increase was confirmed for PWH on DTG + TDF/FTC (+0.16 ± 0.28) and DTG + ABC/3TC (+0.1 ± 0.3). In the SCOLTA cohort, PWH on 2DRs experienced a CD4/CD8 increase only in the DTG + 3TC group. Controlled studies with longer follow-up will clarify the long-term immunological and clinical impacts of DTG-2DR.Keywords
Funding Information
- ViiV Healthcare
This publication has 29 references indexed in Scilit:
- Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell RatioMedicine, 2016
- Determinants of a Low CD4/CD8 Ratio in HIV-1–Infected Individuals Despite Long-term Viral SuppressionClinical Infectious Diseases, 2016
- Lifelong antiretroviral therapy or HIV cure: The benefits for the individual patientAIDS Care, 2015
- CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort studyThe Lancet HIV, 2015
- Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 RatioAIDS Research and Human Retroviruses, 2014
- HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and MortalityPLOS Pathogens, 2014
- Increased Risk of Serious Non-AIDS-Related Events in HIV-Infected Subjects on Antiretroviral Therapy Associated with a Low CD4/CD8 RatioPLOS ONE, 2014
- The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adultsAIDS, 2013
- Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell countsJournal of Antimicrobial Chemotherapy, 2013
- An Italian Approach to Postmarketing Monitoring: Preliminary Results From the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) Project on the Safety of Lopinavir/RitonavirJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005